Sanofi will keep a significant stake in the company ... submit your question by clicking the Q&A icon at the bottom of the screen. Your question will be read by our panelists.

An AI tool called Muse aims to optimize clinical trial patient recruitment and accelerate the development of new therapies.

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Jacobs acknowledged that Novavax does not have the market leverage and scale of French drugmaker Sanofi, with which it signed ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi, France's biggest pharmaceutical group, said last week that it was in talks with CD&R for the sale of a 50% controlling stake in Opella, triggering criticism from government opponents over the ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi ...